PRISM for Depression and Anxiety in Young Adults With Cancer

Last updated: November 25, 2025
Sponsor: Dana-Farber Cancer Institute
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Desmoid Tumors

Anxiety Disorders

Depression

Treatment

Promoting Resilience in Stress Management Program

Clinical Study ID

NCT06502483
24-147
  • Ages 18-39
  • All Genders

Study Summary

This research study is being done to test the feasibility of an existing supportive program (PRISM) to address psychological symptoms (i.e., depressive and anxiety symptoms) that young adult participants diagnosed with cancer or desmoid tumor may experience.

The name of the intervention used in this research study is:

-Promoting Resilience in Stress Management (PRISM) Program

Eligibility Criteria

Inclusion

Inclusion Criteria for Participants:

  1. 18-39 years of age

  2. Speak and comprehend English sufficiently to be able to complete study proceduresand participate in the program in English*

  3. Have been diagnosed with cancer or desmoid tumor at least 6 or more weeks ago

  4. Currently receiving treatment or has completed treatment for cancer or desmoid tumorno more than 6 months ago

  5. Score 10-24 (with question #9 not endorsed, or 0) on the PHQ-9 (Kroenke et al.,

  1. or/and score 10-21 on the GAD-7 (Spitzer et al., 2006) during the initialscreening assessment.

Exclusion

Participant Exclusion Criteria:

  1. Adults unable to consent, individuals who are not yet adults (age <18), pregnantwomen, and prisoners.

  2. Individuals who score less than 10 on both PHQ-9 and GAD-7.

  3. Individuals who are diagnosed with cancer less than 6 weeks at the time of screening (we will be able to approach them again after 6 weeks since diagnosis has passed),or those who completed treatment more than 6 months ago will also be ineligible forthis study; they will be offered resources for support, if desired.

  1. Individuals who report any suicidality (ideation, plan, and/or intent) on PHQ-9 screen (i.e., endorse anything more than 0 for question #9) at the time of the eligibility screening will also be excluded from the current study, and the appropriate safety measures and/or referral to a mental health provider will be made (see section 14.1 for more details on the procedure).

Inclusion Criteria for Support Person:

-≥ 18 years of age

-A friend or family member invited by the study participant to join the 6th PRISM session

Study Design

Total Participants: 15
Treatment Group(s): 1
Primary Treatment: Promoting Resilience in Stress Management Program
Phase:
Study Start date:
September 06, 2024
Estimated Completion Date:
February 01, 2026

Study Description

This research study is being done to test the initial feasibility and acceptability of a six-session, skills-based resilience coaching intervention, Promoting Resilience in Stress Management (PRISM; Rosenberg et al., 2018; Rosenberg et al., 2021), that targets four resilience resources (stress management, goal setting, cognitive reframing, and meaning-making) for young adult patients (18-30 years old) with cancer or desmoid tumor who are treated with curative intent and who report moderate depressive and/or anxiety symptoms.

The research study procedures include screening for eligibility, completing one diagnostic assessment of depressive and anxiety symptoms, pre-intervention and post-intervention questionnaires, completion of the six-session PRISM intervention, and a semi-structured exit interview about the experience with the PRISM intervention.

Participation in this research study is expected to last approximately 2 to 3 months.

It is expected that up to 15 young adults with cancer (i.e., participants) and up to a total of 15 support persons (i.e., friends or family members who participants will have an option to invite for the final session of the intervention) will take part in this research study.

The Hans and Mavis Lopater Foundation is funding this research study by providing philanthropic support.

Connect with a study center

  • Dana-Farber Cancer Institute

    Boston, Massachusetts 02215
    United States

    Site Not Available

  • Dana-Farber Cancer Institute

    Brighton, Massachusetts 02135
    United States

    Site Not Available

  • Dana-Farber Cancer Institute

    Brighton 4931353, Massachusetts 6254926 02135
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.